Health economics and patient outcomes of non-myeloablative hematopoietic stem cell transplantation (HSCT) versus disease-modifying therap (DMT) for relapsing remitting multiple sclerosis in the United States of America

To estimate differences in treatment costs and health outcomes between non-myeloablative hematopoietic stem cell transplantation (HSCT) and disease-modifying therapies (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). Objective To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).

Author(s): Richard K Burt

Abstract | PDF

Share This Article